THDB(SH:600867)2025-10-27 10:05Financial Performance - The company's revenue for the third quarter reached ¥806,097,911.72, representing a year-on-year increase of 13.90% and a cumulative increase of 50.55% year-to-date[4] - The total profit for the year-to-date period was ¥1,185,631,865.28, showing a significant increase of 547.29% compared to the previous year[4] - The net profit attributable to shareholders for the third quarter was ¥984,476,304.01, reflecting a year-on-year increase of 499.86%[4] - The net profit excluding non-recurring gains and losses for the third quarter was ¥100,539,622.11, down 32.24% year-on-year, primarily due to losses from a terminated project[4][10] - Basic and diluted earnings per share for the third quarter were both ¥0.50, an increase of 525.00% year-on-year[5] - Total operating revenue for the first three quarters of 2025 reached CNY 2,179,588,480.01, a significant increase of 50.5% compared to CNY 1,447,720,331.65 in the same period of 2024[25] - The total operating profit for the first three quarters of 2025 was CNY 1,492,757,250.23, compared to a loss of CNY 136,892,789.30 in the same period of 2024[26] - The net profit attributable to shareholders of the parent company reached CNY 1,202,234,367.84, while the net loss was CNY 66,372,427.80 in the previous year[26] - The basic and diluted earnings per share for the current period were CNY 0.61, compared to a loss of CNY 0.03 per share in the same period last year[28] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥380,247,605.21, an increase of 68.88% compared to the previous year[5] - The company's cash and cash equivalents rose to CNY 1,499,224,069.89 as of September 30, 2025, compared to CNY 586,595,200.23 at the end of 2024, representing an increase of 155.5%[21] - The total cash and cash equivalents at the end of the period amounted to CNY 1,499,224,069.89, compared to CNY 332,825,326.83 at the end of the previous year[30] - Cash flow from operating activities generated a net amount of CNY 380,247,605.21, an increase from CNY 225,162,475.15 in the prior year[29] - Cash flow from investing activities showed a net inflow of CNY 904,936,747.69, a significant improvement from a net outflow of CNY 455,059,932.22 in the previous year[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 82,143[12] - Dongbao Industrial Group Co., Ltd. holds 613,823,496 shares, accounting for 31.34% of the total shares, with 565,939,472 shares pledged[12] - Tianjin Zhenyi Equity Investment Partnership holds 183,058,967 shares, representing 9.35% of the total shares[12] - The company plans to transfer 23,187,600 shares of Xiamen Te Bao Bioengineering Co., Ltd. at a price of RMB 56.12 per share, totaling RMB 1,301,288,112[14] - Dongbao Industrial Group plans to increase its shareholding by at least 1% (19,817,341 shares) and up to 2% (39,634,681 shares) within 12 months starting from October 31, 2024[15] - As of October 27, 2025, 22,124,109 shares have been acquired, representing 1.13% of the current total shares[15] - The company approved the 2025 Employee Stock Ownership Plan, with 9,290,000 shares transferred at a price of RMB 4.29 per share[16][17] - The company plans to repurchase shares with a total fund of no less than RMB 20 million and no more than RMB 40 million, aiming to buy back between 200,000 and 400,000 shares[18] - The repurchase price will not exceed RMB 10 per share[18] Investment and R&D - Research and development expenses increased to CNY 116,429,133.17 in the first three quarters of 2025, compared to CNY 75,087,241.78 in 2024, marking a rise of 55%[25] - Investment income for the first three quarters of 2025 was CNY 1,172,543,410.66, a substantial increase from CNY 88,862,833.72 in the same period of 2024[25] - The company reported a non-recurring gain of ¥883,936,681.90 for the year-to-date period, primarily from the transfer of shares in a subsidiary[10] Market and Inventory - The significant increase in revenue was driven by a notable rise in sales of insulin analog products and breakthroughs in overseas markets[9] - The total inventory as of September 30, 2025, was CNY 740,523,999.80, slightly up from CNY 736,309,312.91 at the end of 2024, indicating stable inventory management[21] - The company's total liabilities increased to CNY 1,016,128,667.09 as of September 30, 2025, compared to CNY 978,084,292.41 at the end of 2024, reflecting a rise of 3.9%[23] Future Outlook - The net profit for the first three quarters of 2025 is expected to show a significant improvement due to increased revenue and investment income, although specific guidance was not provided[25] - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[25] Accounting Standards - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[31]